COR at a glance
Cencora (COR, SEC CIK 1140859) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 5, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2025 (FY2025), Cencora (COR) reported revenue of $321.3 billion (up 9.3% from FY2024) and net income of $1.6 billion. Diluted EPS was $7.96.
- As of September 30, 2026, 48 institutional investment managers tracked by SignalX reported holding Cencora (COR) shares worth $25.2 billion in 13F-HR filings.
- In the last 90 days, COR insiders reported 0 open-market purchases ($0) and 5 open-market sales ($5.0M) on Form 4, a net sale of $5.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $321.3B
- +9.3% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$5.0M
- 13F holders
- 48 funds
- $25.2B · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2025
Business Overview
- Core business: Pharmaceutical distribution competing with manufacturers, chain drugstores, specialty distributors, packaging, and healthcare technology firms
- Emphasized regulatory compliance due to new U.S. and EU laws (DSCSA, Falsified Medicines Directive, EU Critical Medicines Act, EU HTA Regulation effective Jan 2025)
- Strategic focus on managing risks from opioid regulation, drug pricing reforms (Inflation Reduction Act, OBBBA), and 340B pricing program disputes and pilot rebate models
- Two largest trade receivables (Walgreens/Boots and Evernorth) represent approx. 43% of net accounts receivable as of Sept 30, 2025
- Noteworthy: Adoption of EU HTA Regulation harmonizing drug assessments starts Jan 12, 2025, with potential major impact on reimbursement decisions and market access
Risk Factors
- Board oversight of cybersecurity delegated to Audit Committee and Compliance and Risk Committee with quarterly meetings and ongoing updates
- CDIO with 25+ years experience and CISO with 20+ years oversee cybersecurity risk management and incident response
- Extended Cyber Crisis Response Team leads containment, recovery, and communication during cyber incidents
- Cybersecurity risk identified by Enterprise Risk Management Team for Board-level oversight and regular risk monitoring
Management Discussion & Analysis
- Revenue $321.3B, up 9.3% YoY; U.S. Healthcare Solutions revenue $291.0B, up 9.7% ($25.6B increase); International Solutions $30.4B, up 6.1% ($1.7B increase)
- Operating margin total 0.82% approx. (operating income $2.63B / revenue $321.3B); U.S. Healthcare margin 1.23%, up 12 bps YoY; International margin decreased 9.1% YoY
- Best segment: U.S. Healthcare Solutions operating income $3.57B, up 21.8% ($639.8M increase); worst segment: International Healthcare Solutions operating income $648M, down 9.1% ($65.1M decrease)
- Cash from operations $3.9B in fiscal 2025, capex $668M; acquisitions $3.9B for RCA; dividends $437.1M paid; share repurchases $435.5M with $882.2M authorization remaining
- Management expects ~$900M capex in 2026; key risks include nonrenewal of customer contracts, opioid litigation payments of $4.3B over 13 years, interest rate and foreign currency exposure, inflation pressures, and geopolitical uncertainties
AI summary of the COR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $84.8B, up 5.1% YoY from $80.7B, driven by U.S. Healthcare Solutions growth
- U.S. Healthcare Solutions strongest segment: revenue $74.9B, up 4.9%; GLP-1 sales $2.3B, up 25.5%
- Gross margin 4.26% vs 3.60% YoY; operating margin 1.32% vs 1.08% YoY
- Operating cash flow $1.7B versus $0.7B YoY; $3.0B senior notes and $1.5B term loans issued for OneOncology
- Outlook: GLP-1 demand supports growth; headwinds include generic conversions, pricing pressure, reimbursement pressure, and customer consolidation
Risk Factors
- No risk-factors section provided; excerpt covers issuer share repurchases only
AI summary of the COR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Cencora announced fiscal fourth-quarter and full-year 2026 earnings for the period ended September 30, 2026
- Earnings release issued November 4, 2026, with financial results and management commentary in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Conference call covers fiscal Q4 and full-year results ended September 30, 2026
- Investor presentation and webcast available at investor.cencora.com
Item EX-99.1: Item EX-99.1
- Q4 revenue $88.4B, up 5.5%, while adjusted EPS rose 21.4% to $4.66, showing strong earnings conversion
- Fiscal 2026 adjusted EPS $17.97, up 12.3%, supported by 20.0% adjusted gross-profit growth and OneOncology contribution
Item 7.01: Regulation FD Disclosure
- Fiscal 2027 reporting shifts to Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
- Reorganization intended to strengthen execution and improve business visibility
Item EX-99.1: Item EX-99.1
- Revised FY2026 revenue $337.4B, up from revised FY2025 $321.3B
- Pharmaceutical Distribution and Services revenue $284.5B, operating income $2.74B
Item 7.01: Regulation FD Disclosure
- Cencora agreed to acquire American Oncology Network through a merger, making AON a wholly owned subsidiary
- Transaction expands Cencora’s oncology platform and creates potential scale, integration, and synergy opportunities
Item EX-99.1: Item EX-99.1
- Acquisition of AON, a 350-plus-provider oncology network across 21 states, expands Cencora’s community-oncology MSO platform
- $2.4B enterprise value, including $2.3B at closing and CVRs of up to $100M
Item 2.02: Results of Operations and Financial Condition
- Cencora updated fiscal year 2026 financial expectations on October 21, 2026
- Preliminary expectations remain subject to closing procedures, final adjustments and management review
AI summaries of COR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for COR
Don't miss the next COR filing
- Alerts as it files. A push when COR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut COR, by share count.
- Ask anything. An AI agent that reads every COR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Mauch Robert P. | F | Nov 12, 2026 | 1,927 | $349.38 |
| Mauch Robert P. | M | Nov 12, 2026 | 4,682 | - |
| Mauch Robert P. | M | Nov 12, 2026 | 4,682 | - |
| Campbell Elizabeth S | M | Nov 12, 2026 | 1,174 | - |
| Verma Pawan | F | Nov 12, 2026 | 676 | $349.38 |
| Verma Pawan | M | Nov 12, 2026 | 1,321 | - |
| Campbell Elizabeth S | M | Nov 12, 2026 | 1,174 | - |
| Verma Pawan | M | Nov 12, 2026 | 1,321 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $294.0B | $321.3B |
| Gross Profit | - | $9.9B | $11.5B |
| Operating Income | - | $2.2B | $2.6B |
| Net Income | - | $1.5B | $1.6B |
| Gross Margin | - | 3.4% | 3.6% |
| Op. Margin | - | 0.7% | 0.8% |
| Net Margin | - | 0.5% | 0.5% |
| Balance Sheet | |||
| Total Assets | $62.6B | $67.1B | $76.6B |
| Equity | $522.0M | $645.9M | $1.5B |
| ROE | - | 233.6% | 103.1% |
| Per Share | |||
| EPS | - | $7.53 | $7.96 |
| Cash Flow | |||
| Operating CF | - | $3.5B | $3.9B |
| CapEx | - | $487.2M | $668.0M |
Source: XBRL data in Cencora (COR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate COR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 48 | $25.20B |
| Q2 2026 | 50 | $25.65B |
| Q1 2026 | 51 | $30.18B |
| Q4 2025 | 51 | $32.11B |
| Q3 2025 | 55 | $31.94B |
| Q2 2025 | 51 | $29.05B |
| Q1 2025 | 50 | $18.66B |
| Q4 2024 | 43 | $11.54B |
- D.E. Shaw & Co+236.3K (+409%)
- Renaissance Technologies LLC+206.6K (+875%)
- Citigroup+169.8K (+61%)
- Dimensional Fund Advisors+50.2K (+3%)
- Bridgewater Associates LP+16.4K (+48%)
- T. Rowe Price Group−1.45M (-20%)
- Invesco Ltd−328.5K (-16%)
- Goldman Sachs Group−274.1K (-12%)
- Morgan Stanley−227.9K (-6%)
- Vanguard Capital Management LLC−207.5K (-2%)
- Blackstone Group+4.8K
- FMR LLC (Fidelity)−4.12M
- StoneX Group Inc.−1.4K
- Equitable Holdings Inc−815
Source: 13F-HR filings on SEC EDGAR (aggregated from 399 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
COR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
Related Health Care companies
- CAH · Cardinal HealthWholesale-Drugs, Proprietaries & Druggists' Sundries
- HLF · HERBALIFE LTD.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- MCK · McKesson CorporationWholesale-Drugs, Proprietaries & Druggists' Sundries
- NUS · NU SKIN ENTERPRISES, INC.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
COR SEC filings: frequently asked questions
Are COR insiders buying or selling?
In the last 90 days, Cencora (COR) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $5.0 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold COR stock?
As of September 30, 2026, the largest Cencora (COR) holders among the 13F filers tracked by SignalX were BlackRock ($5.5 billion), Vanguard Capital Management LLC ($3.7 billion), Vanguard Portfolio Management LLC ($2.8 billion), State Street Corp ($2.8 billion), JPMorgan Chase & Co ($1.8 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was COR's revenue in fiscal year 2025?
For the fiscal year ended September 30, 2025 (FY2025), Cencora (COR) reported revenue of $321.3 billion (up 9.3% from FY2024) and net income of $1.6 billion. Diluted EPS was $7.96. The figures come from the XBRL data in the 10-K.
What are the main risks in COR's latest 10-K?
In the 10-K filed November 25, 2025, Cencora (COR) flagged: Board oversight of cybersecurity delegated to Audit Committee and Compliance and Risk Committee with quarterly meetings and ongoing updates. CDIO with 25+ years experience and CISO with 20+ years oversee cybersecurity risk management and incident response. (AI summary of the Risk Factors section.)
What did COR report in its latest 8-K?
Cencora (COR) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Cencora announced fiscal fourth-quarter and full-year 2026 earnings for the period ended September 30, 2026.
What are the latest COR SEC filings?
Cencora (COR) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 5, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 13, 2026.
What is COR's SEC CIK number?
Cencora (COR)'s SEC Central Index Key (CIK) is 1140859. EDGAR lists every COR filing under that number.
Ask anything about COR
The research agent reads COR's filings, financials, insider trades and 13F holders, then answers with sources.